Tharimmune, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tharimmune, Inc. (Nasdaq: THAR) is a clinical-stage biotechnology company that develops therapeutic candidates targeting unmet needs in immunology, inflammation, and oncology. The company offers a diverse pipeline including its lead asset TH104, a transmucosal film product in Phase II readiness for opioid-induced respiratory and nervous system depression in military and first responders, chronic pruritus in primary biliary cholangitis (PBC), and other pruritogenic inflammatory conditions; TH023 (formerly INT-023), an oral biologic formulation of infliximab leveraging Intract Pharma's Sia and Phloral delivery platforms to treat autoimmune diseases; and early-stage multispecific biologics targeting solid tumors via proprietary EpiClick technology, including candidates against PD-1, HER2, and HER3 epitopes. Tharimmune maintains a license agreement with OmniAb, Inc. for antibody discovery platforms and a research collaboration with Minotaur Therapeutics, Inc. for targeted biologics. Founded in 2017 and headquartered in Bridgewater, New Jersey, the company operates primarily in the United States with global development rights excluding certain regions like Korea. Recent developments include the September 2024 acquisition of a global exclusive license from Intract Pharma for INT-023/TH023, accompanied by a supply agreement for infliximab and options for up to four additional targets, along with a nonbinding letter of intent for a potential merger; a December 2024 private placement raising $2.02 million led by Gravitas Capital and SDS Capital Group to advance TH104 and working capital; a July 2025 registered direct offering of $1.74 million; and a November 2025 $540 million private placement led by DRW and Liberty City Ventures, backed by ARK Invest and others, to pivot toward a Canton Coin-based digital asset treasury strategy while operating blockchain validators. Previously known as Hillstream BioPharma, Inc., Tharimmune rebranded in September 2023 to reflect its immunology focus. The company targets rare diseases, autoimmune disorders, and solid tumors, serving patients through innovative delivery systems and biologics with high unmet medical needs.
Tharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinar
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost
Tharimmune Announces Expanded Role as Super Validator on Canton Network
Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
Tharimmune (NASDAQ:THAR) Stock Price Down 4.1% – Here’s What Happened
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
Tharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl